Press release
BIOTECON Diagnostics GmbH and Biotest AG start wordlwide sales cooperation
In order to enhance the worldwide launch of its innovative Hygiene Screening System, BIOTECON Diagnostics GmbH Potsdam, Germany has started a global sales cooperation with the Business Unit Microbiology of BIOTEST AG in Eppelheim, Germany.In September 2009 the dedicated sales force for the microbiological product range of Biotest AG will start to sell the system for rapid identification of microorganisms from hygiene monitoring samples. Corynebacterium, Staphylococcus, Micrococcus, Kocuria, and Kytococcus can be detected in a simple procedure starting from a single bacterial colony.
“The strength of our Hygiene Screening System lies in a focused product development based on clients’ needs, continuous quality control and excellent performance which is now combined with Biotest’s strength to reach the specific market with its worldwide sales force” emphasizes Alois Schneiderbauer, Chief Business Officer of BIOTECON Diagnostics.
“For our Global Business Unit Microbiology the new molecular biological detection system is a perfect addition to our broad product range in the field of environmental monitoring, including microbial air samplers and Contact Slides. Our customers in the pharmaceutical industry will benefit from this rapid microbiology method for the identification of bacterial colonies grown on our solid media which are optimized for monitoring tests" comments Dr. Frank Schulze, Executive Vice President of the Global Business Unit Microbiology at Biotest AG.
BIOTECON Diagnostics developed the Hygiene Screening System to meet the need for a fast and specific method for environmental monitoring in the pharmaceutical industry. A monitoring study with several pharmaceutical companies revealed that up to 80% of the microorganisms isolated from samples derived from the pharmaceutical environment (personnel, air and surface) belong to the genera Staphylococcus, Micrococcus and Corynebacterium. The method is based on a fast real-time PCR (polymerase chain reaction) technology. A stepwise assignment to either one or other of the mentioned genera is possible within a single PCR reaction in less than two hours.
Since 2004, the usage of more sensitive and specific tests has been recommended by the European Pharmacopoeia (E.P., Chapters 5.1.6 and 2.6.1) and by the FDA Aseptic Guideline with reference to molecular biological methods. There is a need for new methods because most of the conventional methods are time-consuming and sometimes show an insufficient accuracy. The Hygiene Screening System achieves these recommendations by providing an innovative method which allows fast and accurate identification.
BIOTECON Diagnostics GmbH with its headquarter in Potsdam / Berlin (Germany) has been a competent partner for molecular biological and microbiological issues for more than ten years. The focus is the development, production and marketing of PCR-based rapid detection systems. BIOTECON Diagnostics offers solutions for the food and beverages industry as well as for pharmaceutical and cosmetics manufacturers.
Biotest AG is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialized in the areas of application of immunology and haematology. In its Plasma Protein segment, Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. The products of the Microbiological Monitoring segment are primarily used in hygiene monitoring, while those of Medical Diagnostics are used, for example, in blood transfusions and transplants. Biotest has around 2,000 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.
Ken Troia
Director Marketing GBU Microbiology
Wernher-von-Braun-Str. 9
D-69124 Eppelheim
Tel.: +49-6221-72651-34
ken_troia@biotest.de
Benjamin Junge
Product Manager “Pharma Hygiene”
Hermannswerder 17
D-14473 Potsdam
Tel.: +49-331-2300-244
bjunge@bc-diagnostics.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release BIOTECON Diagnostics GmbH and Biotest AG start wordlwide sales cooperation here
News-ID: 92298 • Views: …
More Releases from BIOTECON Diagnostics GmbH
BIOTECON Diagnostics signs license agreement with Applera Corporation
Foster City, Potsdam, May, 2008 Applera and BIOTECON Diagnostics (BCD) announce a non-exclusive, worldwide license agreement relating to PCR technology for Food Testing Applications and Genetically-Modified Organism (GMO) Testing Applications: BIOTECON Diagnostics has acquired important rights with the PCR licence. It enables the company to strengthen its position as an innovative leader in the field of food molecular diagnostics and, together with the food industry, provide even greater food safety.…
BIOTECON Diagnostics acquires LightCycler System Technology License from Roche D …
Mannheim, Potsdam, April, 2008 - BIOTECON Diagnostics, Potsdam and Roche Applied Science, a business unit of Roche Diagnostics have concluded a nonexclusive, worldwide licensing agreement for the development, production and marketing of PCR kits for the LightCycler instrument. The license includes rights for qualitative and quantitative detection and for the identification of harmful germs and genetic modifications in foodstuffs. The combination of Roche´s Light Cycler technology and BIOTECON´s verification procedures…
More Releases for Biotest
Plasma Fractionation Market to Witness Fabulous Growth with CSL, Grifols, Octaph …
According to HTF Market Intelligence, the Global Plasma Fractionation market to witness a CAGR of 6.7% during the forecast period (2024-2030). The Latest Released Plasma Fractionation Market Research assesses the future growth potential of the Plasma Fractionation market and provides information and useful statistics on market structure and size.
This report aims to provide market intelligence and strategic insights to help decision-makers make sound investment decisions and identify potential gaps and…
Hyperimmune Serum Market | ADMA Biologics, Biotest, CBPO, CNBG
The global hyperimmune serum market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the hyperimmune serum market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth of the…
Hyperimmune Globulins Market Outlook and Research| CSL Behring, Grifols, Biotest
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines…
Immunotoxins Market In-Depth Analysis Report 2019| Biotest, Celldex Therapeutics …
Los Angeles, United State, April 16, 2019- The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Immunotoxins market. It includes Porter’s Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Immunotoxins Market. We have provided deep analysis of the vendor…
Blood Plasma Market – Opportunities Summary 2028 | Kedrion S.p.A., Biotest
Global Blood Plasma Market: Overview
Blood plasma and its derivatives form a significant source of medicines. Plasma primarily contains immunoglobulin, clotting factor, and albumin and acts as a vital transporting medium for cells and nutrients in the human body. Recovered plasma has gained traction in the healthcare for the treatment of hemophilia and autoimmune disorders. Apart from that, plasma products are increasingly used in treating a range of conditions, including immune…
Global Hemophilia Treatment Drugs Market Research Report 2017 - Pfizer, Biotest, …
Qyresearchreports include new market research report "Global Hemophilia Treatment Drugs Market Research Report 2017" to its huge collection of research reports.
This is a clear and systematic research report on the distribution for those related with the worldwide Hemophilia Treatment Drugs advertise. The report offers a foreordained estimate period from 2017 to 2022, the most recent portion of this exploration distribution stream. The report offers significant and precise bits of knowledge…